featured
Semaglutide in Patients With HFpEF Across Obesity Class and by Body Weight Reduction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Nat. Med. 2023 Sep 01;29(9)2358-2365, BA Borlaug, DW Kitzman, MJ Davies, S Rasmussen, E Barros, J Butler, MN Einfeldt, GK Hovingh, DV Møller, MC Petrie, SJ Shah, S Verma, W Abhayaratna, FZ Ahmed, V Chopra, J Ezekowitz, M Fu, H Ito, M Lelonek, V Melenovsky, J Núñez, E Perna, M Schou, M Senni, P van der Meer, D Von Lewinski, D Wolf, MN KosiborodFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.